Institutional shares held 6.39 Million
2.2K calls
63.8K puts
Total value of holdings $35M
$12K calls
$348K puts
Market Cap $246M
44,800,500 Shares Out.
Institutional ownership 14.27%
# of Institutions 36


Latest Institutional Activity in KMDA

Top Purchases

Q3 2024
Baader Bank Aktiengesellschaft Shares Held: 20K ($110K)
Q3 2024
Meitav Dash Investments LTD Shares Held: 77.1K ($424K)
Q3 2024
Farther Finance Advisors, LLC Shares Held: 39 ($215)
Q3 2024
Concourse Financial Group Securities, Inc. Shares Held: 0 ($0)
Q2 2024
Y.D. More Investments LTD Shares Held: 726K ($3.99M)

Top Sells

Q2 2024
Phoenix Holdings Ltd. Shares Held: 1.83M ($10.1M)
Q2 2024
Acadian Asset Management LLC Shares Held: 365K ($2.01M)
Q2 2024
Ubs Group Ag Shares Held: 276 ($1.52K)
Q2 2024
Renaissance Technologies LLC Shares Held: 836K ($4.6M)
Q2 2024
Morgan Stanley Shares Held: 2.66K ($14.6K)

About KMDA

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.


Insider Transactions at KMDA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
0 Shares
From 0 Insiders
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on KMDA

Follow KAMADA LTD and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KMDA shares.

Notify only if

Insider Trading

Get notified when an Kamada LTD insider buys or sells KMDA shares.

Notify only if

News

Receive news related to KAMADA LTD

Track Activities on KMDA